Guardant Health (GH) said Tuesday that Palmetto GBA has granted coverage for the Guardant Reveal test to monitor for disease recurrence in colorectal cancer patients after curative intent therapy, expanding from the prior coverage in the early post-surgical setting only.

Palmetto is a Medicare administrative contractor that administers the Molecular Diagnostics Services program, the firm said.

Shares of Guardant Health were up more than 14% in recent trading.

Price: 42.10, Change: +5.44, Percent Change: +14.84